Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer
2023 · Journal of the National Comprehensive Cancer Network · 14 citations
https://doi.org/10.6004/jnccn.2023.7048
L
Lifen Cao
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
67
Papers
444
Citations
11
h-index
13
i10-index
Lifen Cao is an academic researcher from University Hospitals Seidman Cancer Center. The author has contributed to research in topics: Breast Cancer Treatment Studies & Advanced Breast Cancer Therapies & Bioactive Compounds and Antitumor Agents. The author has an h-index of 11, co-authored 57 publications.
ORCID: 0000-0001-9366-7522Papers by this author
worksA comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysis
2022 · Cancer · 9 citations
https://doi.org/10.1002/cncr.34200
Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis
2021 · Breast Cancer Research and Treatment · 4 citations
https://doi.org/10.1007/s10549-021-06411-4
Estimating the overall survival benefit of adjuvant chemo‐endocrine therapy in women over age 50 with <scp>pT1</scp>‐2<scp>N0</scp> early stage breast cancer and 21‐gene recurrence score ≥26: A National Cancer Database analysis
2023 · Cancer Medicine · 1 citations
https://doi.org/10.1002/cam4.6584
Reply to “Select cases might get a benefit from chemotherapy for Stage I <scp>pT1aN0M0 HER2</scp>+ breast cancer”
2022 · Cancer · 0 citations
https://doi.org/10.1002/cncr.34339
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat